Facilitation through hyperventilation of therapeutic effect of pyrithioxin in cerebral infarct patients.
A method of treatment consisting in administration of a neurodynamic drug, pyrithioxin, combined with a short period of hyperventilation (HV) was applied in cerebral infarct patients with hemiplegia. The combination was superior to pyrithioxin alone for the motor recovery of these patients. In some cases, it induced immediately a partial restoration of motility. The combination constantly brought about an increase in urinary excretion of norepinephrine and vanilmandelic acid, which failed to occur after pyrithioxin or HV alone. HV appears to facilitate the neural effects of the drug by promoting its transfer into the CNS.
D000368:Aged; D001812:Blood-Brain Barrier; D002245:Carbon Dioxide / Q000097:blood*; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000628:therapy* / Q000652:urine; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005684:Gait; D006429:Hemiplegia / Q000628:therapy; D006801:Humans; D006985:Hyperventilation / Q000097:blood; D007238:Infarction / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000652:urine; D010313:Partial Pressure; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D011746:Pyrithioxin / Q000627:therapeutic use*; D013997:Time Factors; D014642:Vanilmandelic Acid / Q000652:urine
D010919:Placebos; D011725:Pyridines; D002245:Carbon Dioxide; D014642:Vanilmandelic Acid; D011746:Pyrithioxin; D009638:Norepinephrine